Physician profile
Naheed Alam
NPI 1255592168
$2,773.68
in general payments reported to CMS, 2019-2025
19 companies · $2,084 in 2025
The $2,084 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.27 · 2020: $19.63 · 2022: $42.27 · 2023: $103 · 2024: $462 · 2025: $2,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532 · Travel and Lodging: $1,097 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.81 |
| Travel and Lodging | $1,096.70 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,526.06 | 2024-2025 | Keytruda, Keytruda Qlex |
| Galvanize Therapeutics, INC | $451.42 | 2024-2025 | Aliya System |
| Janssen Biotech, INC. | $235.07 | 2022-2025 | Darzalex, Talvey, Rybrevant |
| Abbvie INC. | $121.03 | 2025 | |
| Adaptive Biotechnologies Corporation | $82.48 | 2023 | Clonoseq |
| Astrazeneca Pharmaceuticals Lp | $72.59 | 2024-2025 | Tagrisso, Enhertu |
| Beone Medicines USA, INC. | $39.86 | 2025 | Tevimbra, Brukinsa |
| Celgene Corporation | $37.18 | 2019-2025 | Reblozyl |
| Geron Corporation | $25.72 | 2025 | Rytelo |
| Novocure INC. | $25.02 | 2025 | Optune Lua (Novottf-200t) |
| Takeda Pharmaceuticals U.S.A., INC. | $24.28 | 2019 | |
| Astellas Pharma US INC | $24.20 | 2025 | Padcev |
| Eisai INC. | $22.22 | 2024 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Janssen Pharmaceuticals, INC | $19.63 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $19.17 | 2025 | |
| Genentech USA, INC. | $14.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.39 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naheed Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.